Biomerica, Inc.
BMRA
$2.71
-$0.08-2.87%
NASDAQ
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.63% | -32.89% | 10.03% | 4.40% | 5.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.63% | -32.89% | 10.03% | 4.40% | 5.49% |
| Cost of Revenue | -37.02% | -9.40% | -5.66% | -3.46% | 16.68% |
| Gross Profit | 46.71% | -1,320.00% | 112.75% | 34.46% | -29.85% |
| SG&A Expenses | -2.21% | -16.76% | -32.89% | -22.88% | 16.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.32% | -12.52% | -22.80% | -17.20% | 7.81% |
| Operating Income | 18.27% | -2.36% | 39.50% | 38.25% | -11.04% |
| Income Before Tax | 100.38% | -8.84% | 39.03% | 36.42% | -18.30% |
| Income Tax Expenses | -25.00% | -28.57% | -200.00% | -137.50% | -82.61% |
| Earnings from Continuing Operations | 100.15% | -8.66% | 39.36% | 36.96% | -16.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.15% | -8.66% | 39.36% | 36.96% | -16.25% |
| EBIT | 18.27% | -2.36% | 39.50% | 38.25% | -11.04% |
| EBITDA | 18.49% | -2.32% | 39.95% | 38.93% | -11.23% |
| EPS Basic | 100.13% | -3.61% | 46.84% | 38.06% | -16.21% |
| Normalized Basic EPS | 100.31% | -3.81% | 46.55% | 37.54% | -18.29% |
| EPS Diluted | 100.13% | -7.32% | 46.84% | 33.33% | -12.50% |
| Normalized Diluted EPS | 100.31% | -3.81% | 46.55% | 37.54% | -18.29% |
| Average Basic Shares Outstanding | 25.46% | 4.87% | 14.06% | 1.78% | 0.02% |
| Average Diluted Shares Outstanding | 25.46% | 4.87% | 14.06% | 1.78% | 0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |